# Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

> **NCT01757535** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 472 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Oral Azacitidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01757535
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-24
- **Primary completion:** 2019-07-15
- **Final completion:** 2024-06-18
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757535, "Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01757535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*